Notre Unité de recherche (UMR-7051) est un centre d'excellence qui intègre recherche fondamentale et clinique pour comprendre le fonctionnement du cerveau et développer des traitements innovants. A l'INP nous étudions l'organisation, la fonction et l'interaction des cellules neurales, les bases moléculaires et cellulaires des principales maladies du cerveau, et développons des stratégies de thérapies cellulaires et moléculaires innovantes.
Très Bonne Année à tou.te.s!!!
Happy new year to all !!
Septins and Microtubules, Conveyors from Cytoskeleton in Cancer cells to Cytoskeleton in Neurons
Pascal Verdier-Pinard CRCN Inserm (invité équipe 7)
Therapeutic resistance is the leading cause of cancer-related mortalities, thus urging the development of more effective treatments for refractory tumors. Drug repurposing, which consists in using existing drugs for new medical indications represents a promising strategy to fast-track novel drug combinations in cancer. However, to increase the success rate in clinical trial of novel therapeutic options, it is essential to fully unravel their molecular mechanisms ofaction. We recently developed an innovative approach, termed reverse molecular pharmacology, which consists in deciphering the poly-pharmacology of existing drugs (either approved or in clinical development) to unveil disease-relevant targetable vulnerabilities. This strategy is based on pharmaco-proteomics to reveal the interactome of drugs within tumor cells.
Dr Eddy Pasquier
